Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study

Roy O. Mathew; Mandeep S. Sidhu; Charanjit S. Rihal; Ryan Lennon; Mohammed El-Hajjar; Neil Yager; Radmila Lyubarova; Khaled Abdul-Nour; Steven Weitz; D. Fearghas O’Cochlain; Vishakantha Murthy; Justin Levisay; Kevin Marzo; John Graham; Vlad Dzavik; Derek So; Shaun Goodman; Yves D. Rosenberg; Naveen Pereira; Michael E. Farkouh

doi:10.1007/s10557-022-07392-2

Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study

Roy O. Mathew
, Mandeep S. Sidhu
, Charanjit S. Rihal
, Ryan Lennon
, Mohammed El-Hajjar
, Neil Yager
, Radmila Lyubarova
, Khaled Abdul-Nour
, Steven Weitz
, D. Fearghas O’Cochlain
, Vishakantha Murthy
, Justin Levisay
, Kevin Marzo
, John Graham
, Vlad Dzavik
, Derek So
, Shaun Goodman
, Yves D. Rosenberg
, Naveen Pereira
, Michael E. Farkouh

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	447-457
Number of pages	11
Journal	Cardiovascular Drugs and Therapy
Volume	38
Issue number	3
DOIs	https://doi.org/10.1007/s10557-022-07392-2
State	Published - Jun 2024
Externally published	Yes

ASJC Scopus Subject Areas

Pharmacology
Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Keywords

Antiplatelet therapy
CYP2C19
Chronic kidney disease
Coronary artery disease
Percutaneous coronary intervention
Pharmacogenomics
Humans
Middle Aged
Male
Purinergic P2Y Receptor Antagonists/adverse effects
Time Factors
Platelet Aggregation Inhibitors/adverse effects
Pharmacogenomic Variants
Female
Kidney/physiopathology
Dual Anti-Platelet Therapy/adverse effects
Percutaneous Coronary Intervention/adverse effects
Risk Assessment
Risk Factors
Treatment Outcome
Genotype
Pharmacogenomic Testing
Renal Insufficiency, Chronic/physiopathology
Coronary Artery Disease
Hemorrhage/chemically induced
Cytochrome P-450 CYP2C19/genetics
Glomerular Filtration Rate/drug effects
Aged

Access to Document

10.1007/s10557-022-07392-2

OpenUrl availability

Full text

Cite this

Mathew, R. O., Sidhu, M. S., Rihal, C. S., Lennon, R., El-Hajjar, M., Yager, N., Lyubarova, R., Abdul-Nour, K., Weitz, S., O’Cochlain, D. F., Murthy, V., Levisay, J., Marzo, K., Graham, J., Dzavik, V., So, D., Goodman, S., Rosenberg, Y. D., Pereira, N., & Farkouh, M. E. (2024). Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovascular Drugs and Therapy, 38(3), 447-457. https://doi.org/10.1007/s10557-022-07392-2

Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. / Mathew, Roy O.; Sidhu, Mandeep S.; Rihal, Charanjit S. et al.
In: Cardiovascular Drugs and Therapy, Vol. 38, No. 3, 06.2024, p. 447-457.

Research output: Contribution to journal › Article › peer-review

Mathew, RO, Sidhu, MS, Rihal, CS, Lennon, R, El-Hajjar, M, Yager, N, Lyubarova, R, Abdul-Nour, K, Weitz, S, O’Cochlain, DF, Murthy, V, Levisay, J, Marzo, K, Graham, J, Dzavik, V, So, D, Goodman, S, Rosenberg, YD, Pereira, N & Farkouh, ME 2024, 'Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study', Cardiovascular Drugs and Therapy, vol. 38, no. 3, pp. 447-457. https://doi.org/10.1007/s10557-022-07392-2

@article{5f29606b640b4810971780f9b6b7b25b,

title = "Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study",

keywords = "Antiplatelet therapy, CYP2C19, Chronic kidney disease, Coronary artery disease, Percutaneous coronary intervention, Pharmacogenomics, Humans, Middle Aged, Male, Purinergic P2Y Receptor Antagonists/adverse effects, Time Factors, Platelet Aggregation Inhibitors/adverse effects, Pharmacogenomic Variants, Female, Kidney/physiopathology, Dual Anti-Platelet Therapy/adverse effects, Percutaneous Coronary Intervention/adverse effects, Risk Assessment, Risk Factors, Treatment Outcome, Genotype, Pharmacogenomic Testing, Renal Insufficiency, Chronic/physiopathology, Coronary Artery Disease, Hemorrhage/chemically induced, Cytochrome P-450 CYP2C19/genetics, Glomerular Filtration Rate/drug effects, Aged",

author = "Mathew, \{Roy O.\} and Sidhu, \{Mandeep S.\} and Rihal, \{Charanjit S.\} and Ryan Lennon and Mohammed El-Hajjar and Neil Yager and Radmila Lyubarova and Khaled Abdul-Nour and Steven Weitz and O{\textquoteright}Cochlain, \{D. Fearghas\} and Vishakantha Murthy and Justin Levisay and Kevin Marzo and John Graham and Vlad Dzavik and Derek So and Shaun Goodman and Rosenberg, \{Yves D.\} and Naveen Pereira and Farkouh, \{Michael E.\}",

note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2024",

month = jun,

doi = "10.1007/s10557-022-07392-2",

language = "English",

volume = "38",

pages = "447--457",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

number = "3",

}

TY - JOUR

T1 - Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease

T2 - a Post Hoc Analysis of the TAILOR-PCI Study

AU - Mathew, Roy O.

AU - Sidhu, Mandeep S.

AU - Rihal, Charanjit S.

AU - Lennon, Ryan

AU - El-Hajjar, Mohammed

AU - Yager, Neil

AU - Lyubarova, Radmila

AU - Abdul-Nour, Khaled

AU - Weitz, Steven

AU - O’Cochlain, D. Fearghas

AU - Murthy, Vishakantha

AU - Levisay, Justin

AU - Marzo, Kevin

AU - Graham, John

AU - Dzavik, Vlad

AU - So, Derek

AU - Goodman, Shaun

AU - Rosenberg, Yves D.

AU - Pereira, Naveen

AU - Farkouh, Michael E.

PY - 2024/6

Y1 - 2024/6

KW - Antiplatelet therapy

KW - CYP2C19

KW - Chronic kidney disease

KW - Coronary artery disease

KW - Percutaneous coronary intervention

KW - Pharmacogenomics

KW - Humans

KW - Middle Aged

KW - Male

KW - Purinergic P2Y Receptor Antagonists/adverse effects

KW - Time Factors

KW - Platelet Aggregation Inhibitors/adverse effects

KW - Pharmacogenomic Variants

KW - Female

KW - Kidney/physiopathology

KW - Dual Anti-Platelet Therapy/adverse effects

KW - Percutaneous Coronary Intervention/adverse effects

KW - Risk Assessment

KW - Risk Factors

KW - Treatment Outcome

KW - Genotype

KW - Pharmacogenomic Testing

KW - Renal Insufficiency, Chronic/physiopathology

KW - Coronary Artery Disease

KW - Hemorrhage/chemically induced

KW - Cytochrome P-450 CYP2C19/genetics

KW - Glomerular Filtration Rate/drug effects

KW - Aged

UR - https://www.scopus.com/pages/publications/85142924959

UR - https://www.scopus.com/pages/publications/85142924959#tab=citedBy

UR - https://www.mendeley.com/catalogue/296d1eba-3970-3970-9367-f5844f2816bc/

U2 - 10.1007/s10557-022-07392-2

DO - 10.1007/s10557-022-07392-2

M3 - Article

C2 - 36445624

AN - SCOPUS:85142924959

SN - 0920-3206

VL - 38

SP - 447

EP - 457

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 3

ER -